17Dec
Related Posts
27May
Next Science (ASX:NXS) – breakthrough antimicrobial technologies
27 May 2021 - Next Science Limited (ASX:NXS) Founder and Chief Technology Officer Dr Matthew Myntti talks about the problem of biofilms, Next Science's antimicrobial treatments and the company's recent FDA approval.
Read More
27Oct
icetana (ASX:ICE) discusses Macnica deal and new product launch
27 Oct 2022 - icetana Limited (ASX:ICE) CEO and Managing Director Matt Macfarlane discusses the company's recent deal with Japanese group Macnica and the launch of a new product.
Read More
31Aug
Acorn Capital on successful investing in junior resource stocks
31 Aug 2020 - Acorn Capital Resources and Energy Analyst Karina Bader talks about junior resource companies and how investors can try to make money as the companies move from explorers to developers to producers.
Read More
19Jun
Buying and selling financial practices
19 Jun 2024 - Steve Prendeville, Founder and Director of Forte Asset Solutions, speaks to Garry Crole, CEO and Managing Director of Sequoia Financial Group (ASX:SEQ). The discussion touches on the market for financial practices, what advisors can do to prepare their business for sale and what to look out for when acquiring a business, among many other topics.
Read More
01Dec
MinRex Resources (ASX:MRR) expands lithium portfolio, November 2021
01 Dec 2021 - MinRex Resources Limited (ASX:MRR) Non-Executive Director George Karageorge provides an update on the company's gold and base metals projects in WA and the Lachlan Ford Belt, NSW and its recently acquired lithium projects in the Pilbara.
Read More
05Nov
The Calmer Co: Bringing kava from Fiji to the world
05 Nov 2024 - Paul Sanger interviews Anthony Noble, CEO of The Calmer Co (ASX:CCO), a leader in sustainable kava production. The Calmer Co aims to become the world's dominant kava company by promoting kava's calming and health benefits while improving the livelihoods of farmers in Fiji through fair pricing and a transparent supply chain.
Read More
30Jul
Clinical trials in cancer and autoimmune diseases: Immutep’s CEO Marc Voigt provides an update
30 Jul 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses Phase III design for a trial in non-small cell lung cancer, positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases.
Read More
05Feb
Aus Tin Mining (ASX:ANW) Taronga drill program
05 Feb 2020 - Aus Tin Mining Limited (ASX:ANW) CEO, Peter Williams, talks about proposed drilling at the company's Taronga tin project and the potential for an upside in tin grades.
Read More
26Nov
Reflecting on progress and partnerships at Immutep
26 Nov 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Read More
13Mar
SUDA Pharmaceuticals (ASX:SUD) 1H20 results & outlook
13 Mar 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker talks 1H20 results progress with the company's lead product Zolpimist, the spay version of Sanofi’s blockbuster insomnia drug Ambien and focus for 2020.
Read More